Citigroup Maintains Neutral on 9 Meters Biopharma, Lowers Price Target to $0.75
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow maintains a Neutral rating on 9 Meters Biopharma (NASDAQ:NMTR) and lowers the price target from $1.7 to $0.75.
May 18, 2023 | 10:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup analyst Samantha Semenkow maintains a Neutral rating on 9 Meters Biopharma and lowers the price target from $1.7 to $0.75.
The lowered price target from Citigroup analyst Samantha Semenkow indicates a bearish outlook on 9 Meters Biopharma's stock. This news is directly related to NMTR and is important for investors as it may lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100